Bachmaier, K. et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 2000; 403:211-216.
Jeon, M.S. et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 2004; 21:67-177.
Krawczyk, C.M. et al. Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b. J Immunol 2005; 174:1472-1478.
Loeser, S et al. The Ubiquitin E3 Ligase Cbl-b in T Cells Tolerance and Tumor Immunity. Cell Cycle 2007; 6(20):2478–2485.
Lutz-Nicoladoni C et al. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine. Immunol Cell Biol. 2012 Jan; 90(1):130-4.
Fujiwara M et al. Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation. Front. Immunol. 2017; 8:42.
Hinterleitner et al. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. PLoS One. 2012; 7(9):e44295
Shusterman et al. Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children’s Oncology Group (COG) Phase II Study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75
Morris et al. In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Res. 2016; 76(13):3929-41
Morris et al. Tumor-specific inhibition of in situ vaccination by distant untreated tumor sites. Cancer Immunol Res. 2018 Jul; 6(7):825-834
Yang et al. Intratumoral hu14.18-IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention. J. Immunol. 2012; 189: 2656–2664
Neri and Sondel. Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol. 2016 Jun; 40:96-102
King et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 2004; 22:4463-73
Wirnsberger et al. Inhibition of CBLB protects from lethal Candida albicans sepsis. Nat Med. 2016 Aug; 22(8):915-23
Lutz-Nicoladoni et al. Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. Front Oncol. 2015 Mar 11; 5:58
Tang et al. Regulation of immune responses by E3 ubiquitin ligase Cbl-b. Cell Immunol. 2018 Nov 7; pii: S0008-8749(18)30430-1
Adams et al. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov. 2015 Sep; 14(9):603-22